LIXTE Biotechnology Co-Sponsoring Cancer Therapy Conference

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, is set to co-sponsor an international scientific workshop titled "Therapeutic Over-Activation in Cancer" at Harvard University’s Dana Farber Cancer Institute on May 9 and 10, 2024, in Boston, Massachusetts. This event aims to gather preeminent scientists from the pharmaceutical industry and academic circles to explore a novel approach to cancer treatment, pioneered by LIXTE’s research team at the Netherlands Cancer Institute.

The innovative strategy, centered on the over-activation of oncogenic signaling in cancer cells, leverages LIXTE’s lead compound, LB-100. Unlike conventional cancer therapies that typically aim to inhibit cancer cell growth, this method seeks to deliberately hyper-activate the signaling pathways that promote cancer cell proliferation, ultimately causing the cancer cells to die. This breakthrough approach has shown significant promise, as detailed in the paper "Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy," recently published online in the scientific journal Cancer Discovery. The study will appear in the journal's July 2024 issue and has revealed that LB-100 can trigger the over-activation of signals leading to uncontrolled cancer cell growth, resulting in cell death.

LIXTE is unique in having a compound in clinical trials capable of over-activating oncogenic signaling. The company is currently conducting three clinical trials testing LB-100's efficacy in enhancing various cancer treatments. Their research indicates that this new treatment paradigm, termed “activation lethality,” could pave the way for novel cancer therapies.

The workshop’s co-leader, Professor René Bernards, Ph.D., from the Netherlands Cancer Institute, and a member of LIXTE’s Board of Directors, is renowned for his expertise in molecular carcinogenesis. He will present findings from a recent pre-clinical study showing that LB-100 can strip cancer cells of their oncogenic properties, providing further evidence of the compound's potential as a transformative cancer treatment.

LIXTE Biotechnology Holdings, Inc. focuses on identifying new drug targets for cancer therapy and developing and commercializing cancer treatments. Their leading clinical compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated tolerability in cancer patients at doses showing anti-cancer activity. Extensive preclinical data suggest that LB-100 could enhance the outcomes of various chemotherapy and immunotherapy regimens. LIXTE’s innovative approach, which currently has no direct competitors, is protected by a broad patent portfolio, with proof-of-concept clinical trials underway.

The company remains committed to advancing its pioneering research and bringing new treatment options to cancer patients, hoping to redefine future cancer therapies.